orion
Third application for Orion’s prostate cancer drug submitted by partner Bayer
September 23, 2024Bayer, Cancer, Oncology, orion, prostate cancer
Finnish pharmaceutical company Orion has announced that its partner Bayer is applying for a third application of its prostate cancer drug, …
Bayer and Orion’s Nubeqa shows off strong overall survival benefit in castration-resistant prostate cancer
January 31, 2020Medical Communications, Research and Development Bayer, orion, pharma
Bayer and Finnish pharma firm Orion Corporation have announced positive new Phase 3 data for their jointly developed oral androgen …
Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer
July 31, 2019Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer
The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …
Bayer, Orion to start Phase III trials for prostate cancer drug
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research
German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
Medea wins European sedative account
January 4, 2010Medical Communications Medea, orion, sedative
Medical communications agency Medea Communications has landed a brief to prepare the ground for a new sedative from Finnish company …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
